<DOC>
	<DOCNO>NCT01565850</DOCNO>
	<brief_summary>This study evaluate safety efficacy darunavir/cobicistat/emtricitabine/tenofovir alafenamide ( D/C/F/TAF ) fix dose combination ( FDC ) tablet versus darunavir ( DRV ) +cobicistat ( COBI ) +emtricitabine ( FTC ) /tenofovir disoproxil fumarate ( TDF ) HIV-1 infect , antiretroviral treatment-naive adult determine achievement HIV-1 RNA &lt; 50 copies/mL Week 24 .</brief_summary>
	<brief_title>D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF HIV-1 Infected , Antiretroviral Treatment Naive Adults</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Adult ( ≥ 18 year ) males nonpregnant female Ability understand sign write informed consent form General medical condition interfere assessment completion trial Plasma HIV1 RNA level ≥ 5,000 copies/mL CD4+ cell count &gt; 50 cells/µL Treatmentnaive : No prior use approve experimental antiHIV drug length time Screening genotype report must show sensitivity DRV , TDF FTC Normal ECG Adequate renal function : Estimated glomerular filtration rate ≥ 70 mL/min accord Cockcroft Gault formula Hepatic transaminases ≤ 2.5 x upper limit normal ( ULN ) Total bilirubin ≤ 1.5 mg/dL Serum amylase ≤ 5 x ULN Adequate hematologic function Normal thyroidstimulating hormone ( TSH ) Females childbearing potential must negative serum pregnancy test Females childbearing potential must agree utilize highly effective contraception method screen throughout duration study treatment 30 day follow last dose study drug Female subject postmenopausal must documentation cessation menses ≥ 12 month hormonal failure Female subject stop menstruate ≥ 12 month documentation ovarian hormonal failure must serum follicle stimulate hormone ( FSH ) level test Male subject must agree utilize highly effective method contraception heterosexual intercourse throughout study period 90 day follow discontinuation investigational medicinal product A new AIDS defining condition diagnose within 30 day prior screen Hepatitis B surface antigen positive Hepatitis C antibody positive Proven acute hepatitis 30 day prior study entry Have history experience decompensated cirrhosis Current alcohol substance use potentially interfere study compliance Any clinical condition prior therapy would make subject unsuitable study unable comply dose requirement History malignancy within past 5 year ongoing malignancy cutaneous Kaposi 's sarcoma ( KS ) , basal cell carcinoma , resect , noninvasive cutaneous squamous carcinoma Females breastfeed Positive serum pregnancy test ( female childbearing potential ) Female subject utilize nonestrogen hormonal contraceptive one birth control method must use method least three month prior study dose Have implant defibrillator pacemaker Active , serious infection ( HIV1 infection ) require parenteral antibiotic antifungal therapy within 30 day prior Baseline Participation clinical trial without prior approval prohibit participate trial Receiving ongoing therapy disallow medication , include drug use darunavir cobicistat Note : darunavir sulfonamide . Participants previously experience sulfonamide allergy allow enter trial . To date , potential cross sensitivity drug sulfonamide class darunavir identify patient participate Phase 2 Phase 3 trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>HIV</keyword>
	<keyword>Treatment-Naive</keyword>
</DOC>